Regeneron Sues Viatris to Halt Biosimilar of Earnings Star Eylea

Regeneron Pharmaceuticals Inc. alleges a biosimilar version of Eylea proposed by a Viatris Inc. unit infringes 24 patents for the drug, used to treat retinal diseases and the source of more than a third of Regeneron’s 2021 revenue, according to a federal lawsuit in West Virginia.

The case, whose complaint was filed Tuesday in the US District Court for the Northern District of West Virginia, landed in the court’s electronic docket Wednesday, as shares of Regeneron rose the most intraday in nearly two years on second-quarter earnings that beat estimates.

Analysts at Piper Sandler & Co. and BMO Capital Markets ...